Media

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Ariceum Therapeutics and Nusano Announce Multi-Isotope Supply Agreement

Intervacc and Dechra extend distribution agreement for Intervacc’s equine strangles vaccine Strangvac by two years

Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma

Spruce Biosciences Announces $50.0 Million Private Placement Financing

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Vicore Pharma – Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis

Gesynta Pharma receives UK approval for a Phase 2 trial of vipoglanstat in endometriosis

Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD)

Intervacc appoints Anna-Carin Lagerlöf as Sales and Marketing Director